Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study

Alice Petty*, Anna Garcia-Hidalgo, Els F. Halff, Sridhar Natesan, Dominic J. Withers, Elaine E. Irvine, Michelle Kokkinou, Lisa A. Wells, David R. Bonsall, Sac Pham Tang, Mattia Veronese, Oliver D. Howes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: There is robust evidence that people with schizophrenia show elevated dopamine (DA) synthesis capacity in the striatum. This finding comes from positron emission tomography (PET) studies using radiolabelled l-3,4-dihydroxyphenylalanine (18F-DOPA). DA synthesis capacity also appears to be elevated in the midbrain of people with schizophrenia compared to healthy controls. We therefore aimed to optimise a method to quantify 18F-DOPA uptake in the midbrain of mice, and to utilise this method to quantify DA synthesis capacity in the midbrain of the sub-chronic ketamine model of schizophrenia-relevant hyperdopaminergia. Procedures: Adult male C57Bl6 mice were treated daily with either ketamine (30 mg/kg, i.p.) or vehicle (saline) for 5 days. On day 7, animals were administered 18F-DOPA (i.p.) and scanned in an Inveon PET/CT scanner. Data from the saline-treated group were used to optimise an atlas-based template to position the midbrain region of interest and to determine the analysis parameters which resulted in the greatest intra-group consistency. These parameters were then used to compare midbrain DA synthesis capacity (K iMod) between ketamine- and saline-treated animals. Results: Using an atlas-based template to position the 3.7 mm3 midbrain ROI with a T*–T end window of 15–140 min to estimate K iMod resulted in the lowest intra-group variability and moderate test–retest agreement. Using these parameters, we found that K iMod was elevated in the midbrain of ketamine-treated animals in comparison to saline-treated animals (t (22) = 2.19, p = 0.048). A positive correlation between DA synthesis capacity in the striatum and the midbrain was also evident in the saline-treated animals (r 2 = 0.59, p = 0.005) but was absent in ketamine-treated animals (r 2 = 0.004, p = 0.83). Conclusions: Using this optimised method for quantifying 18F-DOPA uptake in the midbrain, we found that elevated striatal DA synthesis capacity in the sub-chronic ketamine model extends to the midbrain. Interestingly, the dysconnectivity between the midbrain and striatum seen in this model is also evident in the clinical population. This model may therefore be ideal for assessing novel compounds which are designed to modulate pre-synaptic DA synthesis capacity.

Original languageEnglish
Pages (from-to)1054-1062
Number of pages9
JournalMolecular Imaging and Biology
Volume25
Issue number6
DOIs
Publication statusPublished - Dec 2023

Keywords

  • Dopamine
  • F-DOPA
  • Ketamine
  • Midbrain
  • PET
  • Preclinical
  • Schizophrenia

Fingerprint

Dive into the research topics of 'Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study'. Together they form a unique fingerprint.

Cite this